Abstract 3871: KRAS G12C mutant allele amplification drives resistance to sotorasib in vitro
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3871
Abstract: Sotorasib is an approved KRASG12C-selective inhibitor for the treatment of KRAS p.G12C-mutant advanced and previously treated non-small cell lung cancers (NSCLC). Acquired resistance due to genomic alterations following sotorasib treatment has been observed in 28%… read more here.
Keywords: kras g12c; amplification; resistance; mutant allele ... See more keywords
Abstract B015: Wildtype RAS activity and PI3K signaling as new vulnerabilities in cells with acquired resistance to sotorasib
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-b015
Abstract: Purpose: Sotorasib (AMG510) has demonstrated remarkable response in lung cancer patients with tumors driven by oncogenic KRASG12C mutation. However, recently published clinical data identified acquired mutations in RAS and other genomic alterations as potential mechanisms… read more here.
Keywords: ras activity; lu65 amgr; resistance; pi3k signaling ... See more keywords
Sotorasib Edges Closer to Approval.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2021-0309
Abstract: The KRASG12C inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients and led to a median… read more here.
Keywords: closer approval; approval; edges closer; sotorasib ... See more keywords
Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.9003
Abstract: 9003Background: In the registrational phase 2 CodeBreaK 100 trial, sotorasib demonstrated an objective response rate (ORR) of 37.1% (95% Cl: 28.6, 46.2) and a median progression-free survival (PFS)... read more here.
Keywords: sotorasib; codebreak 100; 100 trial; phase codebreak ... See more keywords
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
Sign Up to like & getrecommendations! Published in 2023 at "Lung Cancer: Targets and Therapy"
DOI: 10.2147/lctt.s403461
Abstract: Abstract Thirteen percent of non-small cell lung cancer (NSCLC) patients are estimated to have the KRAS G12C mutation. Sotorasib is a novel KRAS G12C inhibitor that has shown promising results in preclinical and clinical studies,… read more here.
Keywords: kras g12c; enigma code; trial; codebreak 200 ... See more keywords
Integrative Analysis of Pharmacokinetic and Metabolomic Profiles for Predicting Metabolic Phenotype and Drug Exposure Caused by Sotorasib in Rats
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.778035
Abstract: Sotorasib is a novel targeted inhibitor of Kirsten rat sarcoma (KRAS) (G12C) that has shown exciting tumor-suppressing effects not only for single targeted agents but also for combination with immune checkpoint inhibitors. However, no integrative… read more here.
Keywords: drug exposure; sotorasib; integrative analysis; exposure ... See more keywords
A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24054331
Abstract: Novel inhibitors of KRAS with G12C mutation (sotorasib) have demonstrated short-lasting responses due to resistance mediated by the AKT-mTOR-P70S6K pathway. In this context, metformin is a promising candidate to break this resistance by inhibiting mTOR… read more here.
Keywords: metformin; cell; sotorasib; cytotoxicity apoptosis ... See more keywords
Validation of an LC-MS/MS method for the determination of sotorasib, a KRASG12C inhibitor, in human plasma.
Sign Up to like & getrecommendations! Published in 2022 at "Bioanalysis"
DOI: 10.4155/bio-2022-0173
Abstract: Background: Sotorasib (AMG 510) is a first-in-class KRASG12C inhibitor that received accelerated US FDA approval in 2021 for the treatment of patients with KRASG12C-mutated locally advanced or metastatic non-small-cell lung cancer. Method: An LC-MS/MS method… read more here.
Keywords: human plasma; krasg12c inhibitor; method; determination sotorasib ... See more keywords